AMP Makes Flurry of Trades in Hypo Fund


Today, AMP made a number of trades in its hypothetical fund:

1.) Trimmed its Fibrogen (FGEN) and Uniqure (QURE) down to 10% of the portfolio. Both positions are big winners for AMP; FGEN is up over 200% while QURE's run in the last month has the position up over 100%.

2.) Increased its position in Clearside Biomedical (CLSD)

3.) Increased its position in Array Biopharma (ARRY)


*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

PROUDLY CREATED WITH WIX.COM

  • Twitter Social Icon
  • LinkedIn Social Icon